{
  "id": 9553898,
  "title": "Merck’s return to ophthalmology snags first success",
  "url": "https://urgent.news/2026/09/24/mercks-return-to-ophthalmology-snags-first-success",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T12:14:05.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/mercks-return-to-ophthalmology-snags-first-success/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Merck’s $1.3 billion upfront bet on EyeBio in 2024 is starting to pay off. The New Jersey drug giant, attempting to expand its therapeutic arsenal beyond Keytruda, reported ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}